EUCTR2015-000952-11-IT进行中（未招募）1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy -
TESARO, INCORPORATED0 个研究点目标入组 733 人开始时间: 2021年6月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 733
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Patients must be female =18 years of age, able to understand the study procedures and agree to participate in the study by providing written informed consent
- •2.a. Patients must have histologically diagnosed high-grade serous or endometrioid, or high-grade predominantly serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that is Stage III or IV according to FIGO criteria
- •3. Surgical criteria:
- •a. Patients with inoperable Stage III and IV disease are eligible;
- •b. All Stage IV patients with operable disease are eligible;
- •c. Patients with stage III or IV disease treated with neoadjuvant chemotherapy and interval debulking surgery are eligible;
- •d. Patients with stage III disease who have visible residual disease after primary debulking surgery are eligible .
- •4. Chemotherapy criteria:
- •a. Patients who have received intraperitoneal chemotherapy are eligible;
- •b. All patients must have had =6 and =9 cycles of platinum-based therapy;
- •Patients must have had =2 post-operative cycles of platinum-based therapy following interval debulking surgery;
- •d. Patients must have physician assessed CR or PR after = 3 cycles of therapy;
- •e. Patients must have either CA-125 in the normal range or CA-125 decrease by more than 90% during their front-line therapy that is stable
- •for at least 7 days (ie, no increase >15% from nadir)
- •5. Patients must be randomized within 12 weeks of the first day of the last cycle of chemotherapy.
- •6. All patients must agree to undergo central tumor HRD testing.
- •a. The central HRD test result must be available for randomization as it is a stratification factor. Patients with documented gBRCA1 or gBRCA2
- •mutation or sBRCA1/2 mutation may be randomized without HRD test results
- •b. The tumor sample may be submitted for HRD testing prior to the screening period if it appears the patient is likely to meet other eligibility
- •requirements. Patients are not required to have repeat HRD testing if HRD result is not determined (eg, due to insufficient tumor specimen)
- •c. Patients with known HRD test results from any commercially available sources including Myriad Genetics are allowed to participate in the
- •study; however, they must still agree to submit a tumor sample for central HRD testing. The results of the central HRD testing must be available prior to randomization and must be used for stratification.
- •7. Patients of childbearing potential must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin [hCG]) within 7
- •days prior to receiving the first dose of study treatment
- •8. Patients must be postmenopausal, free from menses for >1 year, surgically sterilized, or willing to use adequate contraception to prevent
- •pregnancy (see Appendix A) or must agree to abstain from activities that could result in pregnancy throughout the study, starting with enrollment
- •through180 days after the last dose of study treatment
- •9. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Please refer to protocol for further criteria.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 574
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 468
排除标准
- •1. Patient has mucinous or clear cell subtypes of epithelial ovarian cancer, carcinosarcoma or undifferentiated ovarian cancer
- •2. Patient is Stage III disease who have had complete cytoreduction (i.e., no visible residual disease) after primary debulking surgery
- •3. Patient has undergone more than two debulking surgeries
- •4. Patient is pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and for up to 180 days after the last dose of study treatment;
- •5. Patient has a known hypersensitivity to the components of niraparib or its excipients
- •6. Patient is simultaneously enrolled in any clinical trial of niraparib or any other investigational therapy
- •7. Patient has received prior treatment with a known PARP inhibitor or has participated in a study where any treatment arm included administration of a known PARP inhibitor
- •8. Patient is to receive bevacizumab as maintenance treatment. Patients who have received bevacizumab with their first-line platinum based
- •therapy but are unable to receive bevacizumab as maintenance therapy due to adverse events or for any other reason are not excluded from study as long as the last dose of bevacizumab was received = 28 days prior to signing the main informed consent form;
- •9. Patient has had investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the
- •investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study
- •10. Patient has had any known =Grade 3 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted >4 weeks
- •11. Patient has any known history or current diagnosis of MDS or AML;
- •12. Patient has undergone major surgery (per Investigator judgment) within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery;
- •13. Patient has had drainage of ascites within 4 weeks prior to enrollment;
- •14. Patient has undergone palliative radiotherapy encompassing >20% of the bone marrow within 1 week of the first dose of study treatment;
- •15. Patient has a condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment, including:
- •a. Patient received a transfusion (platelets or red blood cells) within 2 weeks of the first dose of study treatment;
- •b. Patient received colony-stimulating factors (eg, granulocyte colony stimulating factor [G-CSF], granulocyte macrophage colony-stimulating
- •factor [GM-CSF] or recombinant erythropoietin) within 2 weeks prior to the first dose of study treatment.
- •16. Patient is planning to donate blood during the study or for 90 days after the last dose of study treatment.
- •17. Patient has been diagnosed and/or treated for invasive cancer less than 5 years prior to study enrollment. Note: Patients with definitively
- •treated uterine cervical or urinary tract carcinoma in situ, nonmelanomatous skin cancer or ductal carcinoma in situ (DCIS) of the breast are not excluded
- •Please refer to protocol for further criteria.
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravisEUCTR2019-000968-18-CZCB Biopharma SR240
进行中（未招募）
1 期
Efficacy and safety of Cabozantinib (XL184) in subjects who have progressed after VEGFR-targeted treatmentRadioiodine-Refractory Differentiated Thyroid Cancer which has progressed after priorVEGFR-targeted therapyMedDRA version: 20.0Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001771-21-CZExelixis, Inc.300
进行中（未招募）
1 期
A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)EUCTR2016-004148-13-PTGilead Sciences, Inc.800
招募中
1 期
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancerung Cancer, Non-Small CellMedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-508443-40-00Glaxosmithkline Research & Development Limited644